Clinical Trials on HER2-positive Bladder Cancer in Ireland

Total 105 results

QuantumLeap Healthcare Collaborative

Recruiting

PRE-I-SPY Phase I/Ib Oncology Platform Program (PRE-I-SPY-PI)

Solid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditions

United States
Cancer Trials Ireland

Completed

Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer

Breast Cancer | HER2 Positive Breast Cancer | HER2 Negative Breast Cancer

Ireland
Cancer Trials Ireland

Terminated

CharactHer. ICORG 12-09, V3

HER2-positive Breast Cancer | TNM Stage II-IV Breast Cancer

Ireland, Italy
Cancer Trials Ireland

Recruiting

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

HER2-positive Breast Cancer

Ireland
Cancer Trials Ireland

Terminated

The Myocet/Lapatinib Study. ICORG 10-03, V5

Her2 Positive Metastatic Breast Cancer

Ireland
Cancer Trials Ireland

Completed

Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) (Panther)

HER2 Positive Breast Cancer

Ireland
Cancer Trials Ireland

Terminated

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer (Panthera)

Metastatic Breast Cancer | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Cancer

Ireland, Spain
Daiichi Sankyo

Completed

EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan (EUROPA T-DXd)

HER2-positive Breast Cancer

Spain, Ireland, Italy
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone... and other conditions

United States
Novartis Pharmaceuticals

Completed

A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy

HR+/HER2- Advanced or Metastatic Breast Cancer

Ireland
National Cancer Institute (NCI)

Completed

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7

United States, Puerto Rico
European Organisation for Research and Treatment...
Breast International Group; Menarini Group

Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (TREAT ctDNA)

Stage IIB Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Stage III Breast Cancer

Belgium, Italy, Ireland, France, Germany
Dana-Farber Cancer Institute
Genentech, Inc.

Recruiting

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Breast Cancer | HER2-positive Breast Cancer

United States
Brown University
Lifespan

Terminated

Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin

Bladder Cancer | Invasive Bladder Cancer

United States
NRG Oncology
National Cancer Institute (NCI); Alliance for Clinical Trials in Oncology; Eastern... and other collaborators

Recruiting

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer (HERO)

HER2-positive Breast Cancer

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
National Cancer Institute (NCI)

Completed

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Recurrent Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | HER2 Positive Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
Seagen Inc.
Merck Sharp & Dohme LLC

Recruiting

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)

HER2 Positive Breast Cancer

United States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
German Breast Group
Pfizer; AGO Study Group; Breast International Group; NSABP Foundation Inc

Completed

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery (PENELOPE-B)

Breast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG Score

United States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
Daiichi Sankyo, Inc.
AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...

Active, not recruiting

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

HER2-Positive Primary Breast Cancer | Residual Invasive Breast Cancer

United States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
Puma Biotechnology, Inc.

Terminated

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

Metastatic Cervical Cancer | Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Spain, Israel, United States, Serbia, France, Ireland, Italy
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Bayer; United States Department of Defense; Canadian...

Terminated

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Node Positive HER2 Negative Breast Cancer

United States, Canada, Puerto Rico, Guam
Brown University
Cures Within Reach; Lifespan; Legorreta Cancer Center at Brown University

Recruiting

Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant (TASUC-Neo)

Urothelial Carcinoma Bladder | Androgen Receptor Positive

United States
Genentech, Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Korea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | HER2/Neu Positive

United States, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

HER2/Neu Negative | Estrogen Receptor-positive Breast Cancer | Stage IV Breast Cancer AJCC v6 and v7

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Elevated CA15-3 or CEA or CA27-29

United States, Puerto Rico, Guam
National Cancer Institute (NCI)
Radiation Therapy Oncology Group

Completed

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Bladder Urothelial Carcinoma | Stage I Bladder Cancer AJCC v6 and v7 | Stage II Bladder Cancer AJCC v6 and v7 | Stage III Bladder Cancer AJCC v6 and v7

United States, Canada
Medical Diagnostic Laboratories, LLC

Unknown

Efficacy Study of a Urine DEK ELISA for Diagnosis of Bladder Cancer

Bladder Cancer | Hematuria | Dysuria

United States
University College Cork
Irish Cancer Society; Cancer Research@UCC

Recruiting

Linking In With Advice and Supports for Men Impacted by Metastatic Cancer (LIAM Mc)

Kidney Cancer | Prostate Cancer | Penile Cancer | Survivorship | Testicular Cancer | Urothelial Tract/Bladder Cancer, Nos

Ireland
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Recurrent Breast Carcinoma | HER2/Neu Positive | Progesterone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States, Canada, Puerto Rico, Ireland
CG Oncology, Inc.

Recruiting

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Bladder Cancer | Urothelial Carcinoma | Urologic Cancer | Non Muscle Invasive Bladder Cancer

United States
AstraZeneca

Completed

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Bladder Cancer | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer | Transitional Cell Bladder Cancer

United States, Spain, United Kingdom, Germany, Canada
Spectrum Pharmaceuticals, Inc
Allergan

Terminated

Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer

United States, Poland, Czechia, Slovakia
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Canadian Cancer Trials Group; Southwest Oncology... and other collaborators

Completed

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

HER2 Positive Breast Carcinoma | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Peru, South Africa
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | HER2-Positive Breast Carcinoma | Hormone Receptor-Positive Breast Carcinoma

United States, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Bladder Cancer

Canada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
Butler Hospital
National Cancer Institute (NCI)

Completed

Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking

Kidney Cancer | Cervical Cancer | Leukemia | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Tobacco Use Disorder | Lung Cancer | Bladder Cancer | Liver Cancer

United States
National Cancer Institute (NCI)
Southwest Oncology Group

Completed

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

Recurrent Breast Carcinoma | HER2 Positive Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Bladder Urothelial Carcinoma | Stage IIIA Bladder Cancer AJCC v8 | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

United States
MacroGenics

Completed

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA)

HER-2 Positive Breast Cancer | Metastatic Neoplasm

United States, Spain, Italy, Canada, Israel, Belgium, Germany, Czechia, Austria, Korea, Republic of, Denmark, United Kingdom, Portugal, France, Poland, Netherlands, Finland, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes (The INSPIRE Study)

Stage III Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma

United States
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)

Muscle-invasive Bladder Cancer

Belgium, Korea, Republic of, Japan, Brazil, China, United States, Singapore, France, United Kingdom, Canada, Greece, Italy, Spain, Turkey, Russian Federation, Ukraine, Israel, Czechia, Colombia, Hong Kong, Argentina, Germany, Ireland, Polan... and more
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United Kingdom, Korea, Republic of, Australia, United States, Spain
Onxeo

Completed

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Ovarian Cancer | Fallopian Tube Cancer | Bladder Cancer | Epithelial Ovarian Cancer

United States, Denmark, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Unresectable Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Metastatic HER2-Negative Breast Carcinoma | Unresectable HER2-Negative Breast Carcinoma | Locally Advanced HER2-Negative...

United States
University of Washington
National Cancer Institute (NCI)

Completed

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

United States
Janssen Research & Development, LLC

Completed

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Postmenopausal | Metastatic ER+ Her2- Breast Cancer

United States, France, Ukraine, United Kingdom, Belgium, Spain, Netherlands, Korea, Republic of, Russian Federation, Poland, Luxembourg, Ireland
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

Bladder Cancer

United States, Canada

Clinical Trials on HER2-positive Bladder Cancer in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations